CTOs on the Move

Innovate Biopharmaceuticals

www.innovatebiopharma.com

 
Innovate is a clinical stage biotechnology company developing novel medicines for gastroenterological disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Innovate Biopharmaceuticals raised $21M on 01/30/2018

Similar Companies

Bio Clean USA

Bio Clean USA is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Saskatchewan Research Council

Saskatchewan Research Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IGM Biosciences

IGM Biosciences, Inc. is a privately held biotechnology company that has been focused on creating and developing novel IgM and IgA antibodies that improve the treatment of cancer and other diseases since 2010.

ADMA Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...

Lineage Cell

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage`s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage`s clinical assets include (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.